JanuaryEnVAX-A71 vaccine has passed NDA conducted by Ministry of Health and Welfare.
2022
AugustSpeedy COVID-19 Ag Rapid Test has obtained formal medical equipment import approval in Indonesia, and can be marketed and sold in the country.
JunePCL SELF TEST - COVID19 Ag project has started selling in Taiwan.
AprilENIMMUNE issued new shares totaling NT$58,000,000, making paid-in capital reach NT$658,000,000.
FebruaryCOVID-19 Antigen Self Test has obtained approval for manufacturing under the Ministry of Health and Welfare's epidemic prevention project.
2021
NovemberEstablished a joint venture company with AIOS BIOTECH PTE. LTD. from Singapore.
NovemberEnVAX-A71 vaccine has obtained approval from the Ministry of Health of Vietnam to conduct overseas phase III IND.
MarchSpeedy COVID-19 Ag Rapid Test has been granted approval for manufacturing and sale by the Ministry of Health and Welfare's epidemic prevention project.
JanuarySigned a technology licensing agreement with the Industrial Technology Research Institute to develop nucleic acid reagents for COVID-19 saliva testing.
2020
DecemberThe Speedy COVID-19 Ag Rapid Test obtained CE-IVD certification.
NovemberReceived funding from the R&D fixed-cost project of the Ministry of Economic Affairs.
SeptemberSigned a joint development agreement with Abcombi Biosciences Inc., a biotechnology company in the United States, for the development of a pneumococcal vaccine.
MayThe EnVAX-A71 vaccine applied for NDA to the Taiwan Ministry of Health and Welfare.
March The new drug application is to be made after the Phase III enterovirus vaccine trial meets the standard.
MarchENIMMUNE passed the GDP compliance evaluation.
2019
April The designated number of people signing up for the Phase III enterovirus vaccine trial in Taiwan was met.
February The new drug investment program was approved.
2018
September ENIMMUNE (stock code: 6564) went public on the emerging stock board, TPEx.
AugustENIMMUNE issued new shares totaling NT$40,000,000, making paid-in capital reach NT$440,000,000.
June The Phase III enterovirus vaccine trial commenced.
2017
DecemberThe clinical study report (CSR) on the Phase II enterovirus vaccine trial (Bioreactor Process) was issued.
August The application for the Phase II enterovirus vaccine trial (Bioreactor Process) commenced.
2016
NovemberThe clinical study report (CSR) for the Phase II enterovirus vaccine trial (Roller bottle Process) was issued.
JuneApproval of the Phase II IND for the enterovirus vaccine trial (Bioreactor) in the pediatric population.
2015
NovemberENIMMUNE announced initial public offering (IPO).
SeptemberA third party was entrusted to complete the factory inspection requested by the Ministry of Health and Welfare.
July126 people were vaccinated in the Phase II enterovirus vaccine trial (phaseⅡa).
2014
DecemberThe Phase II enterovirus vaccine trial (phaseⅡa) was approved by the Ministry of Health and Welfare.
FebruaryENIMMUNE issued new shares totaling NT$316,000,000, making paid-in capital reach NT$400,000,000.
JanuaryEnimmune Corp. was founded with paid-in capital of NT$84,000,000
